Management of the Dialysis Patient with Sickle Cell Disease

Seminars in Dialysis

Volumn 29, Issue 1, 2016, Pages 62-70

  Boyle, Suzanne M ^a   Jacobs, Benjamin ^b   Sayani, Farzana A ^b   Hoffman, Brenda ^c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLICATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE, CHRONIC; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 85000774260     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/sdi.12403     Document Type: Article

References (72)

1. Available at http://www.cdc.gov/ncbdd/sicklecell/data/html, accessed June 27, 2015
2. Powars DR, Elliott-Mills DD, Chan L, Niland J, Hiti AL, Opas LM, et al.: Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med 115:614-620, 1991
3. McClellan AC, Luthi JC, Lynch JR, Soucie JM, Kulkarni R, Guasch A, et al.: High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol 159:360-367, 2012
4. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C: Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 84:363-376, 2005
5. Abbott KC, Hypolite IO, Agodoa LY: Sickle cell nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 58:9-15, 2002
6. Hoffman R, Benz E, Silberstein L, Heslop H, Weitz J, Anastasi J: Hematology: Basic Principles and Practice. Philadelphia, PA: Elsevier Saunders, 2013
7. Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Kshirsagar AV: High prevalence of sickle cell trait in African Americans with ESRD. J Am Soc Nephrol 21:413-417, 2010
8. Schmalzer EA, Lee JO, Brown AK, Usami S, Chien S: Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion 27:228-233, 1987
9. Embury SH, Dozy AM, Miller J, Davis JR Jr, Kleman KM, Preisler H, et al.: Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med 306:270-274, 1982
10. Davies SC, Roberts-Harewood M: Blood transfusion in sickle cell disease. Blood Rev 11:57-71, 1997
11. Rees DC, Olujohungbe AD, Parker NE, Stephens AD, Telfer P, Wright J; British Committee for Standards in Haematology General Haematology Task Force by the Sickle Cell Working Party: Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol 120: 744-752, 2003
12. Lucania G, Vitrano A, Filosa A, Maggio A: Chelation treatment in sickle-cell-anaemia: much ado about nothing? Br J Haematol 154:545-555, 2011
13. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al.: Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339:5-11, 1998
14. Rees DC, Williams TN, Gladwin MT: Sickle-cell disease. Lancet 376:2018-2031, 2010
15. Brittenham GM: Iron-chelating therapy for transfusional iron overload. N Engl J Med 364:146-156, 2011
16. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F: Natural History of Sickle Cell Anemia in Saudi ArabsA Study of 270 Subjects. Ann Intern Med 88:1-6, 1978
17. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al.: Pain in sickle cell disease. N Engl J Med 325:11-16, 1991
18. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al.: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332:1317-1322, 1995
19. Steinberg MH, Barton F, Castro O, Pegelow C, Ballas SK, Kutlar A, et al.: Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289:1645-1651, 2003
20. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
21. Friedman EA, Rao TK, Sprung CL, Smith A, Manis T, Bellevue R, et al.: Uremia in sickle-cell anemia treated by maintenance hemodialysis. N Engl J Med 291:431-435, 1974
22. Nagel RL, Vichinsky E, Shah M, Johnson R, Spadacino E, Fabry ME, et al.: F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood 81:9-14, 1993
23. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF: Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 323:366-372, 1990
24. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW: Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 328:73-80, 1993
25. Breen CP, Macdougall IC: Improvement of erythropoietin-resistant anaemia after renal transplantation in patients with homozygous sickle-cell disease. Nephrol Dial Transplant 13:2949-2952, 1998
26. Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, et al.: Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica 91:1076-1083, 2006
27. Roger SD, Macdougall IC, Thuraisingham RC, Raine AE: Erythropoietin in anemia of renal failure in sickle cell disease. N Engl J Med 325:1175-1176, 1991
28. Schettler V, Wieland E: A case report of darbepoetin treatment in a patient with sickle cell disease and chronic renal failure undergoing regular hemodialysis procedures that induce a dose-dependent extension of blood transfusion intervals. Ther Apher Dial 13:80-82, 2009
29. Steinberg MH: Erythropoietin for anemia of renal failure in sickle cell disease. N Engl J Med 324:1369-1370, 1991
30. Tomson CR, Edmunds ME, Chambers K, Bricknell S, Feehally J, Walls J: Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 7:817-821, 1992
31. Zumrutdal A: Response of patients with sickle cell anaemia and end-stage renal disease to erythropoietin treatment. NDT Plus 3:328-330, 2010
32. Chawla LS, Krishnan M: Causes and consequences of inflammation on anemia management in hemodialysis patients. Hemodial Int 13:222-234, 2009
33. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al.: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74:791-798, 2008
34. K. A. W. Group: KDIGO Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2:279-335, 2012
35. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, deZeeuw D, Eckardt KU, et al. ; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
36. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. ; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
37. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
38. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. ; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
39. Derebail VK, Lacson EK Jr, Kshirsagar AV, Key NS, Hogan SL, Hakim RM, et al.: Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose. J Am Soc Nephrol 25:819-826, 2014
40. Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Rosamond WD, et al.: Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. Kidney Int 80:992-999, 2011
41. Sharpe CC, Thein SL: How I treat renal complications in sickle cell disease. Blood 123:3720-3726, 2014
42. Porter J., Garbowski M.: Consequences and management of iron overload in sickle cell disease. Hematol Am Soc Hematol Educ Program 2013:447-456, 2013
43. Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O: Circumstances of death in adult sickle cell disease patients. Am J Hematol 81:858-863, 2006
44. Brown K, Subramony C, May W, Megason G, Liu H, Bishop P, et al.: Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy. J Pediatr Hematol Oncol 31:309-312, 2009
45. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, et al. ; on behalf of the Dialysis Advisory Group of the American Society of Nephrology: Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis. J Am Soc Nephrol 26: 1238-1247, 2015
46. Yusuf B, McPhedran P, Brewster UC: Hypocalcemia in a dialysis patient treated with deferasirox for iron overload. Am J Kidney Dis 52:587-590, 2008
47. Falk RJ, Mattern WD, Lamanna RW, Gitelman HJ, Parker NC, Cross RE, et al.: Iron removal during continuous ambulatory peritoneal dialysis using deferoxamine. Kidney Int 24:110-112, 1983
48. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, et al.: Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 125: 991-999 e991, 2012
49. Ghoti H, Rachmilewitz EA, Simon-Lopez R, Gaber R, Katzir Z, Konen E, et al.: Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 89:87-93, 2012
50. Kan WC, Chien CC, Wu CC, Su SB, Hwang JC, Wang HY: Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients. Nephrol Dial Transplant 25:1604-1608, 2010
51. Roxe DM, Krumlovsky FA, Del Greco F, Fitzsimons E: Failure of deferoxamine to improve iron overload in chronic hemodialysis patients. Int J Artif Organs 13:211-217, 1990
52. Winchester JF: Management of iron overload in dialysis patients. Semin Nephrol 6:22-26, 1986
53. Gomez RA, Campbell F, Savory J, Chevalier RL: Deferoxamine for the treatment of hemosiderosis during CAPD. Int J Pediatr Nephrol 8:21-24, 1987
54. Maker GL, Siva B, Batty KT, Trengove RD, Ferrari P, Olynyk JK: Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. Nephrology 18:188-193, 2013
55. Tsai CW, Yang FJ, Huang CC, Kuo CC, Chen YM: The administration of deferasirox in an iron-overloaded dialysis patient. Hemodial Int 17:131-133, 2013
56. Frenette PS: Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 9:101-106, 2002
57. Wanner C, Drechsler C, Krane V: C-reactive protein and uremia. Semin Dial 22:438-441, 2009
58. Glassberg J: Evidence-based management of sickle cell disease in the emergency department. Emerg Med Pract 13: 1-20; quiz 20, 2011
59. Mousa SA, Al Momen A, Al Sayegh F, Al Jaouni S, Nasrullah Z, Al Saeed H, et al.: Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clin Appl Thromb Hemost 16:365-376, 2010
60. Wyne A, Rai R, Cuerden M, Clark WF, Suri RS: Opioid and benzodiazepine use in end-stage renal disease: a systematic review. Clin J Am Soc Nephrol 6:326-333, 2011
61. Perlman R, Giladi H, Brecht K, Ware MA, Hebert TE, Joseph L, et al.: Intradialytic clearance of opioids: methadone versus hydromorphone. Pain 154:2794-2800, 2013
62. Dean M: Opioids in renal failure and dialysis patients. J Pain Symptom Manage 28:497-504, 2004
63. Platt OS: Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 358:1362-1369, 2008
64. Yan JH, Ataga K, Kaul S, Olson JS, Grasela DM, Gothelf S, et al.: The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. J Clin Pharmacol 45:434-445, 2005
65. Kassim AA, DeBaun MR: Sickle cell disease, vasculopathy, and therapeutics. Annu Rev Med 64:451-466, 2013
66. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al.: A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 365:44-53, 2011
67. Abassi Z, Nakhoul F, Khankin E, Reisner SA, Yigla M: Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Curr Opin Nephrol Hypertens 15:353-360, 2006
68. Di Lullo L, Floccari F, Rivera R, Barbera V, Granata A, Otranto G, et al.: Pulmonary hypertension and right heart failure in chronic kidney disease: new challenge for 21st-century cardionephrologists. Cardiorenal Med 3:96-103, 2013
69. Holley JL: General medical care of the dialysis patient: core Curriculum 2013. Am J Kidney Dis 61:171-183, 2013
70. Minniti CP, Delaney KM, Gorbach AM, Xu D, Lee CC, Malik N, et al.: Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia. Am J Hematol 89:1-6, 2014
71. Minniti CP, Eckman J, Sebastiani P, Steinberg MH, Ballas SK: Leg ulcers in sickle cell disease. Am J Hematol 85:831-833, 2010
72. Huang E, Parke C, Mehrnia A, Kamgar M, Pham PT, Danovitch G, et al.: Improved survival among sickle cell kidney transplant recipients in the recent era. Nephrol Dial Transplant 28:1039-1046, 2013